A Pilot " Window-3 " Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Conditions:   Lymphoma;   Mantle Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Drug: Rituximab;   Other: Brexucabtagene Autoleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate Sponsors:   M.D. Anderson Cancer Center;   Kite, A Gilead Company;   Acerta Pharma, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials